8-K: Graphite Bio Announces Reverse Stock Split and Name Change to Lenz Therapeutics Ahead of Merger

Graphite Bio will enact a 1-for-7 reverse stock split and change its name to Lenz Therapeutics on March 21, 2024, in preparation for its merger with Lenz Therapeutics.

Summary

• Graphite Bio is merging with Lenz Therapeutics, with Lenz becoming a wholly-owned subsidiary of Graphite.
• Prior to the merger, Graphite's shareholders approved a reverse stock split at a ratio of 1-for-7.
• The company will also change its name to Lenz Therapeutics, Inc.
• The reverse stock split and name change will be effective at 4:01 p.m. Eastern Time on March 21, 2024.
• Each 7 shares of Graphite common stock will be combined into one new share of common stock.
• No fractional shares will be issued; instead, shareholders will receive cash for any fractional shares.
• The common stock will begin trading on a split-adjusted basis under the ticker symbol LENZ on March 22, 2024.
• The par value per share of the common stock will remain unchanged.
• Adjustments will be made to outstanding equity awards under the company's stock option plans to reflect the reverse stock split.

Sentiment

Score: 7

Explanation: The document outlines a planned corporate action (merger, reverse stock split, name change) which is generally positive for the company's future. There are no negative surprises, but the future success of the merger is not guaranteed.

Positives

• The merger with Lenz Therapeutics is progressing as planned.
• The reverse stock split and name change are key steps in the merger process.
• The company is providing cash payments for fractional shares, which is beneficial for shareholders.

Risks

• The success of the merger is subject to the satisfaction of closing conditions.
• The company's future performance is subject to various risks and uncertainties, as detailed in their SEC filings.
• There is no guarantee that the anticipated benefits of the merger will be realized.

Future Outlook

The document includes forward-looking statements regarding the merger, the combined company's listing on Nasdaq, future operations, and clinical development activities, but cautions that actual results may differ due to various risks and uncertainties.

Management Comments

• Graphite's board of directors previously approved a final ratio of 1-for-7 for the Reverse Stock Split, subject to stockholder approval.

Industry Context

This announcement reflects a strategic move by Graphite Bio to merge with Lenz Therapeutics, likely to consolidate resources and expertise in the biotechnology sector. Mergers and acquisitions are common in the biotech industry as companies seek to expand their pipelines and market reach.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies to increase their share price and maintain listing requirements, particularly in the biotech sector where stock prices can be volatile.
• The merger process is similar to other biotech mergers, involving shareholder approvals, regulatory filings, and integration of operations.
• The name change to Lenz Therapeutics is a typical step in a merger where the acquiring company adopts the name of the target company or a new name to reflect the combined entity.

Stakeholder Impact

• Shareholders will experience a reverse stock split and receive cash for fractional shares.
• Shareholders will see the company's name change to Lenz Therapeutics.
• The company's stock will trade under a new ticker symbol, LENZ.

Next Steps

• The company will file a certificate of amendment to effect the reverse stock split and name change on March 21, 2024.
• The common stock will begin trading under the new ticker symbol LENZ on March 22, 2024.

Key Dates

Keywords

Merger, Reverse Stock Split, Name Change, Lenz Therapeutics, Graphite Bio, Stock Symbol, Corporate Action